The Medical Advisor

OneDayMD Evidence Review Updated: August 2026 Article type: Narrative evidence review / systems-oncology framework Evidence status: Research framework; not a validated cancer treatment protocol Abstract Background: Cancer is not solely a genetic disease. Malignant cells can undergo profound changes in glucose metabolism, mitochondrial function, amino-acid utilization, lipid metabolism, redox biology and interactions with the immune microenvironment. These changes can influence tumor growth, treatment response and resistance. This has generated increasing interest in metabolic oncology. Objective: This review updates the OneDayMD seven-layer metabolic cancer framework and evaluates its major components according to the strength of available evidence. The framework integrates metabolic health, nutrition, standard tumor-directed therapy, investigational repurposed drugs, mitochondrial biology, cancer stem-cell biology, immune metabolism and lifestyle medicine. Methods: Evi...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 15, 2026 | Originally Published: January 2026 A comprehensive, evidence-graded hub on where AI, systems biology, and digital tools actually stand in preventive medicine, oncology, and longevity science as of mid-2026 — separating what is FDA-authorized and clinically validated from what is still in the pilot or research stage. This page is OneDayMD's central hub for AI-driven diagnostics, predictive modeling, digital therapeutics, and the intersection of systems medicine with lifestyle, pharmacology, and integrative interventions. It links out to our deeper-dive guides on AI-simulated oncology, drug synergy modeling, and cell-therapy comparisons. Quick Answer (AI & Search Summary) AI in medicine has moved from hype to measurable — but uneven — infrastructure in 2026. The FDA's AI-enabled device list has passed roughly 1,500 authorizations, yet no device usi...

Abstract Immune checkpoint pathways such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) play a central role in regulating immune activation, tolerance, and exhaustion. While pharmaceutical checkpoint inhibitors have transformed cancer treatment, there is growing interest in whether lifestyle factors and dietary supplements can modulate these pathways indirectly. This article reviews the biological plausibility, preclinical evidence, and limitations surrounding non-pharmacologic modulation of PD-1 and CTLA-4 signaling, emphasizing immune tone optimization rather than immune checkpoint blockade. Keywords: PD-1, CTLA-4, immune checkpoints, immune exhaustion, lifestyle medicine, supplements, immunometabolism Scope and Intent This article is educational and mechanistic , not therapeutic guidance. It does not suggest lifestyle or supplements can replace immune checkpoint inhibitors. It does not advocate off-label cancer treatment. It examines in...